Minerva Neurosciences | NERV - Debt


Minerva Neurosciences reported $0 in Debt for its fiscal quarter ending in September of 2024.





Debt Change Date
Acadia Pharmaceuticals USD 52.19M 2.62M Dec/2025
Adma Biologics USD 204.41M 121.28M Mar/2026
ALKERMES USD 1.58B 1.51B Mar/2026
Alterity Therapeutics Limited AUD 210.39K 120.67K Jun/2023
AstraZeneca USD 33.92B 4.3B Mar/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Cipla INR 4.38B 231.9M Mar/2025
Clal Biotechnology ILS 35.76M 28.27M Dec/2023
Compugen USD 2.93M 14K Mar/2026
CSL USD 11.96B 219M Dec/2024
Eli Lilly USD 42.5B 3.6M Dec/2025
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Grifols EUR 9.23B 626.05M Dec/2024
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
J&J USD 47.93B 2.14B Dec/2025
Merck USD 49.34B 7.97B Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novartis USD 47B 11.62B Mar/2026
Novavax USD 233.31M 4.23M Sep/2024
Pfizer USD 63.73B 231M Mar/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sanofi EUR 20.33B 1.43B Dec/2025
Takeda JPY 4.85T 208B Dec/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024